1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

Australia Relaxes Competition Rules To Facilitate Coronavirus Response

Generic And Brand Industry Bodies Team Up To Tackle COVID-19

 
• By Dave Wallace

Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

Game_Snakes_Ladders
The ACCC has relaxed the rules around competition in Australia to allow the collaboration • Source: Shutterstock

A “conditional interim authorization” to allow generic and brand industry associations in Australia to work together to share information on stock levels, inventory, manufacturing and the supply chain as part of efforts to address the coronavirus pandemic has been granted by the Australian Competition and Consumer Commission. However, discussions of tender pricing will not be included among the permitted conduct.

Australia’s originator body Medicines Australia had on 27 March applied to the ACCC seeking authorization for an initial six-month period for it and the Generic and Biosimilar Medicines Association “to implement a co-ordinated strategy in relation to the supply of essential medicines and related supplies in response to the current COVID-19 pandemic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

More from Policy & Regulation